Drugs / AZD4045
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07681596 | Jul 2026 → Oct 2029 expected | refractory plasma cell neoplasm | AstraZeneca | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681596 ↗ |
| Modality | Cell therapy | “Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy” NCT07681596 ↗ |